## Omics Group Journals
### Subject wise

<table>
<thead>
<tr>
<th>Omics</th>
<th>ISSN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Computer Science &amp; Systems Biology</td>
<td>0974-7230</td>
</tr>
<tr>
<td>Data Mining in Genomics &amp; Proteomics</td>
<td>2153-0602</td>
</tr>
<tr>
<td>Glycomics &amp; Lipomics</td>
<td>2153-0637</td>
</tr>
<tr>
<td>Health &amp; Medical Informatics</td>
<td>2157-7420</td>
</tr>
<tr>
<td>Metabolomics: Open Access</td>
<td>2153-0769</td>
</tr>
<tr>
<td>Pharmacogenomics &amp; Pharmacoproteomics</td>
<td>2153-0645</td>
</tr>
<tr>
<td>Proteomics &amp; Bioinformatics</td>
<td>0974-276X</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chemistry</th>
<th>ISSN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analytical &amp; Bioanalytical Techniques</td>
<td>2155-9872</td>
</tr>
<tr>
<td>Chromatography &amp; Separation Techniques</td>
<td>2157-7094</td>
</tr>
<tr>
<td>Medicinal Chemistry</td>
<td>2161-0444</td>
</tr>
<tr>
<td>Organic Chemistry</td>
<td>2161-0401</td>
</tr>
<tr>
<td>Physical Chemistry &amp; Biophysics</td>
<td>2161-0398</td>
</tr>
<tr>
<td>Thermodynamics &amp; Catalysis</td>
<td>2157-7544</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pharmaceutical Sciences</th>
<th>ISSN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advances in Pharmacopoeidology &amp; Drug Safety</td>
<td>2167-1052</td>
</tr>
<tr>
<td>Antivirals &amp; Antiretrovirals</td>
<td>1948-5994</td>
</tr>
<tr>
<td>Bioanalysis &amp; Biomedicine</td>
<td>1948-593X</td>
</tr>
<tr>
<td>Bioequivalence &amp; Bioavailability</td>
<td>0975-0851</td>
</tr>
<tr>
<td>Clinical Pharmacology &amp; Biopharmaceutics</td>
<td>2107-905X</td>
</tr>
<tr>
<td>Drug Metabolism &amp; Toxicology</td>
<td>2157-7609</td>
</tr>
<tr>
<td>Outlook on Developing Drugs: Open Access</td>
<td>2167-0714</td>
</tr>
<tr>
<td>Pharmaceutica Analytica Acta</td>
<td>2153-2435</td>
</tr>
<tr>
<td>Pharmaceutical Regulatory Affairs: Open Access</td>
<td>2167-7689</td>
</tr>
<tr>
<td>Vaccines &amp; Vaccination</td>
<td>2157-7560</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical</th>
<th>ISSN</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIDS &amp; Clinical Research</td>
<td>2155-6113</td>
</tr>
<tr>
<td>Anesthesia &amp; Clinical Research</td>
<td>2155-6148</td>
</tr>
<tr>
<td>Cancer Science &amp; Therapy</td>
<td>1948-5956</td>
</tr>
<tr>
<td>Carcogenesis &amp; Mutagenesis</td>
<td>2157-2518</td>
</tr>
<tr>
<td>Cell Science &amp; Therapy</td>
<td>2157-7013</td>
</tr>
<tr>
<td>Clinical &amp; Cellular Immunology</td>
<td>2155-9699</td>
</tr>
<tr>
<td>Clinical &amp; Experimental Cardiology</td>
<td>2155-9880</td>
</tr>
<tr>
<td>Clinical &amp; Experimental Dermatology Research</td>
<td>2155-9554</td>
</tr>
<tr>
<td>Clinical &amp; Experimental Ophthalmology</td>
<td>2155-9570</td>
</tr>
<tr>
<td>Clinical &amp; Experimental Pathology</td>
<td>2161-0681</td>
</tr>
<tr>
<td>Clinical &amp; Experimental Pharmacology</td>
<td>2161-1459</td>
</tr>
<tr>
<td>Clinical Research &amp; Bioethics</td>
<td>2155-9627</td>
</tr>
<tr>
<td>Clinical Toxicology</td>
<td>2161-0495</td>
</tr>
<tr>
<td>Cytology &amp; Histology</td>
<td>2157-7099</td>
</tr>
<tr>
<td>Forensic Research</td>
<td>2157-7145</td>
</tr>
<tr>
<td>Integrative Oncology</td>
<td></td>
</tr>
<tr>
<td>Neurology &amp; Neuropsychology</td>
<td>2155-9552</td>
</tr>
<tr>
<td>Pulmonary &amp; Respiratory Medicine</td>
<td>2161-105X</td>
</tr>
<tr>
<td>Stem Cell Research &amp; Therapy</td>
<td>2157-7633</td>
</tr>
<tr>
<td>Transplantation Technologies &amp; Research</td>
<td>2161-0991</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Management</th>
<th>ISSN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounting &amp; Marketing</td>
<td>2156-9901</td>
</tr>
<tr>
<td>Business &amp; Financial Affairs</td>
<td>2157-0234</td>
</tr>
<tr>
<td>Civil &amp; Legal Sciences</td>
<td>2160-0170</td>
</tr>
<tr>
<td>Defense Management</td>
<td>2107-0374</td>
</tr>
<tr>
<td>Entrepreneurship &amp; Organization Management</td>
<td>2156-026X</td>
</tr>
<tr>
<td>Hotel &amp; Business Management</td>
<td>2156-0266</td>
</tr>
<tr>
<td>Mass Communication &amp; Journalism</td>
<td>2105-7912</td>
</tr>
<tr>
<td>Socialomics</td>
<td>2157-0358</td>
</tr>
<tr>
<td>Stock &amp; Forex Trading</td>
<td>2166-0458</td>
</tr>
<tr>
<td>Tourism &amp; Hospitality</td>
<td>2157-0269</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Engineering</th>
<th>ISSN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advances in Automobile Engineering</td>
<td>2167-7770</td>
</tr>
<tr>
<td>Advances in Robotics &amp; Automation</td>
<td>2168-9395</td>
</tr>
<tr>
<td>Aeronautics &amp; Aerospace Engineering</td>
<td>2168-9702</td>
</tr>
<tr>
<td>Applied Mechanical Engineering</td>
<td>2168-9873</td>
</tr>
<tr>
<td>Architectural Engineering Technology</td>
<td>2168-9717</td>
</tr>
<tr>
<td>Astrophysics &amp; Aerospace Technology</td>
<td></td>
</tr>
<tr>
<td>Bioprocessing &amp; Biotechniques</td>
<td>2155-9521</td>
</tr>
<tr>
<td>Chemical Engineering &amp; Process Technology</td>
<td>2157-7048</td>
</tr>
<tr>
<td>Civil &amp; Environmental Engineering</td>
<td>2166-784X</td>
</tr>
<tr>
<td>Electrical &amp; Electronics</td>
<td>2167-101X</td>
</tr>
<tr>
<td>Food Processing &amp; Technology</td>
<td>2157-7110</td>
</tr>
<tr>
<td>Geology &amp; Geosciences</td>
<td></td>
</tr>
<tr>
<td>Geophysics &amp; Remote Sensing</td>
<td>2169-0049</td>
</tr>
<tr>
<td>Industrial Engineering &amp; Management</td>
<td>2169-0316</td>
</tr>
<tr>
<td>Information Technology &amp; Software Engineering</td>
<td>2166-7866</td>
</tr>
<tr>
<td>Irrigation &amp; Drainage Systems Engineering</td>
<td>2166-9766</td>
</tr>
<tr>
<td>Material Sciences &amp; Engineering</td>
<td>2169-0022</td>
</tr>
<tr>
<td>Powder Metallurgy &amp; Mining</td>
<td>2168-9806</td>
</tr>
<tr>
<td>Telecommunications System &amp; Management</td>
<td>2167-0919</td>
</tr>
<tr>
<td>Textile Science &amp; Engineering</td>
<td>2165-8064</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Environmental</th>
<th>ISSN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aquaculture Research &amp; Development</td>
<td>2155-9546</td>
</tr>
<tr>
<td>Earth Science &amp; Climatic Change</td>
<td>2157-7617</td>
</tr>
<tr>
<td>Ecosystem &amp; Ecography</td>
<td>2157-7625</td>
</tr>
<tr>
<td>Environmental &amp; Analytical Toxicology</td>
<td>2161-0525</td>
</tr>
<tr>
<td>Geography &amp; Natural Disasters</td>
<td>2167-0667</td>
</tr>
<tr>
<td>Hydrology: Current Research</td>
<td>2157-7587</td>
</tr>
<tr>
<td>Petroleum &amp; Environmental Biotechnology</td>
<td>2157-7463</td>
</tr>
</tbody>
</table>

### About OMICS

OMICS Publishing Group is an Open Access publication model with a mission to influence, encourage and assist scientists that enables the dissemination of research articles to the global community. It provides an open forum to share on science and technology and research policies around the globe and contributes to the creation of an integrated space for science and technology.

OMICS Publishing Group also organizes meetings at the international level and this focus has successfully led to the expansion of the group into rising scientific areas and an ability to innovate, especially in the digital layout.

Contact us at: contact.omics@omicsonline.org
<table>
<thead>
<tr>
<th>Life Sciences</th>
<th>ISSN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agrotechnology</td>
<td>2168-9981</td>
</tr>
<tr>
<td>Bacteriology &amp; Parasitology</td>
<td>2155-9597</td>
</tr>
<tr>
<td>Biochemistry &amp; Analytical Biochemistry</td>
<td>2161-1009</td>
</tr>
<tr>
<td>Biochemistry &amp; Pharmacology</td>
<td>2161-0501</td>
</tr>
<tr>
<td>Biochemistry &amp; Physiology</td>
<td>2168-9952</td>
</tr>
<tr>
<td>Biochips &amp; Tissue Chips</td>
<td>2153-0777</td>
</tr>
<tr>
<td>Bioenergetics</td>
<td>2167-7662</td>
</tr>
<tr>
<td>Bioengineering &amp; Biomedical Science</td>
<td>2155-9538</td>
</tr>
<tr>
<td>Biostabilizers &amp; Biopesticides</td>
<td>2155-6202</td>
</tr>
<tr>
<td>Biostatistics</td>
<td>2155-6180</td>
</tr>
<tr>
<td>Biomedical Research &amp; Therapeutics</td>
<td>2167-7956</td>
</tr>
<tr>
<td>Biomediation &amp; Biodegradation</td>
<td>2155-6199</td>
</tr>
<tr>
<td>Biosafety</td>
<td>2167-0331</td>
</tr>
<tr>
<td>Biosensors &amp; Bioelectronics</td>
<td>2155-6210</td>
</tr>
<tr>
<td>Biotechnology &amp; Biomaterials</td>
<td>2155-952X</td>
</tr>
<tr>
<td>Bioterrorism &amp; Biodefense</td>
<td>2157-2528</td>
</tr>
<tr>
<td>Cell &amp; Developmental Biology</td>
<td>2168-9296</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>2167-7700</td>
</tr>
<tr>
<td>Enzyme Engineering</td>
<td>2167-7972</td>
</tr>
<tr>
<td>Fermentation Technology</td>
<td>2167-7972</td>
</tr>
<tr>
<td>Forest Research: Open Access</td>
<td>2166-9976</td>
</tr>
<tr>
<td>Fungal Genomics &amp; Biology</td>
<td>2165-8056</td>
</tr>
<tr>
<td>Marine Science Research &amp; Development</td>
<td>2155-9910</td>
</tr>
<tr>
<td>Medical Advancements in Genetic Engineering</td>
<td>2169-0111</td>
</tr>
<tr>
<td>Medicinal &amp; Aromatic Plants</td>
<td>2167-0412</td>
</tr>
<tr>
<td>Membrane Science &amp; Technology</td>
<td>2155-9589</td>
</tr>
<tr>
<td>Microbial &amp; Biochemical Technology</td>
<td>1948-5948</td>
</tr>
<tr>
<td>Molecular Imaging &amp; Dynamics</td>
<td>2155-9937</td>
</tr>
<tr>
<td>Nanomedicine &amp; Electrotherapeutic Discovery</td>
<td>2155-983X</td>
</tr>
<tr>
<td>Nanomedicine &amp; Nanotechnology</td>
<td>2157-7439</td>
</tr>
<tr>
<td>Nutrition &amp; Food Sciences</td>
<td>2155-9800</td>
</tr>
<tr>
<td>Plant Pathology &amp; Microbiology</td>
<td>2157-7471</td>
</tr>
<tr>
<td>Primalogy</td>
<td>2167-6001</td>
</tr>
<tr>
<td>rDNA Technology</td>
<td>2169-0008</td>
</tr>
<tr>
<td>Single Cell Genomics &amp; Proteomics</td>
<td>2168-9431</td>
</tr>
<tr>
<td>Social &amp; Economical Issues of Biotechnology</td>
<td>2157-7552</td>
</tr>
<tr>
<td>Tissue Science &amp; Engineering</td>
<td>2157-7579</td>
</tr>
<tr>
<td>Veterinary Science &amp; Technology</td>
<td>2167-0390</td>
</tr>
<tr>
<td>Vitamins &amp; Trace Elements</td>
<td>2167-0420</td>
</tr>
<tr>
<td>Women's Health Care</td>
<td>2157-7595</td>
</tr>
<tr>
<td>Yoga &amp; Physical Therapy</td>
<td>2157-7595</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medical Sciences</th>
<th>ISSN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Addiction Research &amp; Therapy</td>
<td>2155-6105</td>
</tr>
<tr>
<td>Air &amp; Water borne Diseases</td>
<td>2167-7719</td>
</tr>
<tr>
<td>Allergy &amp; Therapy</td>
<td>2155-6121</td>
</tr>
<tr>
<td>Alzheimer's Disease &amp; Parkinosis</td>
<td>2161-0460</td>
</tr>
<tr>
<td>Anaesthesiology</td>
<td>2101-1173</td>
</tr>
<tr>
<td>Anatomy &amp; Physiology</td>
<td>2161-0940</td>
</tr>
<tr>
<td>Andrology</td>
<td>2167-0250</td>
</tr>
<tr>
<td>Arthritis</td>
<td>2167-7921</td>
</tr>
<tr>
<td>Autocoids</td>
<td>2161-0479</td>
</tr>
<tr>
<td>Blood &amp; Lymph</td>
<td>2165-7831</td>
</tr>
<tr>
<td>Blood Disorders &amp; Transfusion</td>
<td>2155-8664</td>
</tr>
<tr>
<td>Brain Disorders &amp; Therapy</td>
<td>2168-975X</td>
</tr>
<tr>
<td>Clinical Case Reports</td>
<td>2165-7920</td>
</tr>
<tr>
<td>Clinical Trials</td>
<td>2167-0970</td>
</tr>
<tr>
<td>Cloning &amp; Transgenesis</td>
<td>2168-9949</td>
</tr>
<tr>
<td>Communicable &amp; Noncommunicable Diseases</td>
<td>2161-0711</td>
</tr>
<tr>
<td>Community Medicine &amp; Health Education</td>
<td>2161-0711</td>
</tr>
</tbody>
</table>

| Dentistry                      | 2161-1122  |
| Depression & Anxiety          | 2167-1044  |
| Diabetes & Metabolism         | 2155-6156  |
| Drug Designing                | 2169-0138  |
| Emergency Medicine            | 2165-7548  |
| Endocrinology & Metabolic Syndrome | 2161-1017 |
| Entomology, Omithology & Herpetology | 2161-0983 |
| Epidemiology: Open Access     | 2161-1165  |
| Ergonomics                    | 2165-7556  |
| Fertilization : In Vitro      | 2165-7491  |
| Gastrointestinal & Digestive System | 2161-0698 |
| Genetic Syndromes & Gene Therapy | 2157-7412 |
| Gerontology & Geriatrics Research | 2167-7182 |
| Gynecobiology                 | 2166-856X  |
| Gynecology & Obstetrics       | 2161-0922  |
| Hair: Therapy & Transplantation| 2167-5951  |
| Hereditary Genetics           | 2161-1041  |
| Homeopathic Medicine          | 2167-1206  |
| Human Genetics & Embryology   | 2161-0436  |
| Hypertension: Open Access     | 2167-1095  |
| Internal Medicine             | 2165-8048  |
| Liver                         | 2167-0869  |
| Medical & Surgical Urology    | 2168-8857  |
| Medical Diagnostic Methods    | 2168-8764  |
| Medical Microbiology & Diagnosis | 2161-0703 |
| Metabolic Syndrome            | 2167-0943  |
| Molecular Biology             | 2168-9547  |
| Molecular Biomarkers & Diagnosis | 2159-9899 |
| Mycobacterial Diseases        | 2161-1088  |
| Neonatal Biology              | 2167-0897  |
| Nephrology & Therapeutics     | 2161-6999  |
| Novel Physicotherapies        | 2165-7025  |
| Nuclear Medicine & Radiation Therapy | 2165-6619 |
| Nursing & Care                | 2167-1168  |
| Nutritional Disorders & Therapy| 2161-0509 |
| Obesity & Weight loss Therapy | 2165-7904  |
| OMICS Journal of Radiology    | 2107-7964  |
| Organ Biology                 | 2168-6822  |
| Orthopedic & Muscular System  | 2161-0533  |
| Otolaryngology                | 2161-119X  |
| Pain & Relief                 | 2167-0846  |
| Palliative Care & Medicine    | 2165-7386  |
| Pancreatic Disorders & Therapy| 2165-7092  |
| Pediatrics & Therapeutics     | 2161-0665  |
| Primary Health Care: Open Access | 2167-1079 |
| Psychology & Psychotherapy    | 2161-0467  |
| Reproductive System & Sexual Disorders | 2161-038X |
| Rheumatology: Current Research | 2161-1149  |
| Sleep Disorders & Therapy     | 2167-0277  |
| Spine                         | 2165-7939  |
| Sports Medicine & Doping Studies | 2161-0673 |
| Steroids & Hormonal Science   | 2157-7536  |
| Surgery: Current Research     | 2161-1076  |
| Thyroid Disorders & Therapy   | 2167-7948  |
| Translational Medicine        | 2161-1025  |
| Trauma & Treatment            | 2167-1222  |
| Virology & Mycology           | 2161-0517  |

OMICS Group Inc., 2360 Corporate Circle, Suite 400
Henderson, NV 89074-3722, USA
Ph: +1-888-843-8169, Fax: +1-605-618-1417
E-mail: info@omicsgroup.org / info@omicsonline.org
### Impact Factors (IF) and Index Copernicus Values (ICV)

<table>
<thead>
<tr>
<th>OMICS Publishing Group - Journal Name</th>
<th>PubMed Abbreviation</th>
<th>IF</th>
<th>ICV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Journal of Analytical &amp; Biocatalytic Techniques</td>
<td>J Anal Biocatal Tech</td>
<td>2.63</td>
<td>5.33</td>
</tr>
<tr>
<td>Journal of Addiction Research &amp; Therapy</td>
<td>J Addict Res Ther</td>
<td>1.13</td>
<td>5.22</td>
</tr>
<tr>
<td>Journal of Aquaculture Research &amp; Development</td>
<td>J Aquacult Res Dev</td>
<td>0.62</td>
<td>5.15</td>
</tr>
<tr>
<td>Journal of Allergy &amp; Therapy</td>
<td>J Allergy Ther</td>
<td>1.07</td>
<td>4.47</td>
</tr>
<tr>
<td>Journal of Antivirals &amp; Antiretrovirals</td>
<td>J Antivir Antiretrovir</td>
<td>2.05</td>
<td>4.81</td>
</tr>
<tr>
<td>Journal of Biometrics &amp; Bioinformatics</td>
<td>J Biom Biostat</td>
<td>1.5</td>
<td>4.47</td>
</tr>
<tr>
<td>Journal of Bioequivalence &amp; Bioavailabilty</td>
<td>J Bioequiv Availab</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Journal of Biotechnology &amp; Biomedicine</td>
<td>J Biomed Biomed</td>
<td>1.21</td>
<td>5.17</td>
</tr>
<tr>
<td>Journal of Biosensors &amp; Bioelectronics</td>
<td>J Biosens Bioclectron</td>
<td>3.57</td>
<td>-</td>
</tr>
<tr>
<td>Journal of Biotechnology &amp; Biodefense</td>
<td>J Biotechnology Biodefense</td>
<td>1.27</td>
<td>4.66</td>
</tr>
<tr>
<td>Journal of Bioremediation &amp; Biodegradation</td>
<td>J Bioremed Biodeg</td>
<td>3.5</td>
<td>5.07</td>
</tr>
<tr>
<td>Journal of Cancer Science &amp; Therapy</td>
<td>J Cancer Sci Ther</td>
<td>4.25</td>
<td>5.09</td>
</tr>
<tr>
<td>Journal of Clinical &amp; Experimental Ophthalmology</td>
<td>J Clin Exp Ophthalmol</td>
<td>0.5</td>
<td>4.9</td>
</tr>
<tr>
<td>Journal of Cardiology &amp; Cardiovascular</td>
<td>J Cardiovasc Cardio</td>
<td>4.1</td>
<td>5.04</td>
</tr>
<tr>
<td>Journal of Chemical Engineering &amp; Process Technology</td>
<td>J Chem Eng Process Technol</td>
<td>1.07</td>
<td>5.3</td>
</tr>
<tr>
<td>Journal of Clinical &amp; Experimental Cardiology</td>
<td>J Clin Exp Cardiol</td>
<td>2.11</td>
<td>4.45</td>
</tr>
<tr>
<td>Journal of Clinical &amp; Cellular Immunology</td>
<td>J Clin Cell Immun</td>
<td>1.14</td>
<td>4.1</td>
</tr>
<tr>
<td>Journal of Clinical Research &amp; Bioinformatics</td>
<td>J Clin Res Biochem</td>
<td>1.13</td>
<td>5.27</td>
</tr>
<tr>
<td>Journal of Clinical &amp; Experimental Dermatology</td>
<td>J Clin Exp Dermatol</td>
<td>2.53</td>
<td>5.01</td>
</tr>
<tr>
<td>Journal of Cytology &amp; Histology</td>
<td>J Cytol Histol</td>
<td>2.07</td>
<td>4.81</td>
</tr>
<tr>
<td>Journal of Chromatography &amp; Separation Techniques</td>
<td>J Chromat Separation Techniq</td>
<td>1.33</td>
<td>4.55</td>
</tr>
<tr>
<td>Journal of Ductlining in Genomics &amp; Proteomics</td>
<td>J Ductlining Genomics Proteomics</td>
<td>3.21</td>
<td>6.07</td>
</tr>
<tr>
<td>Journal of Drug Metabolism &amp; Toxicology</td>
<td>J Drug Metab Toxicol</td>
<td>1.27</td>
<td>4.4</td>
</tr>
<tr>
<td>Journal of Earth Science &amp; Climatic Change</td>
<td>J Earth Sci Climate Change</td>
<td>0.66</td>
<td>-</td>
</tr>
<tr>
<td>Journal of Food Processing &amp; Technology</td>
<td>J Food Process Technol</td>
<td>2.15</td>
<td>4.87</td>
</tr>
<tr>
<td>Journal of Forensic Research</td>
<td>J Forensic Res</td>
<td>0.05</td>
<td>4.4</td>
</tr>
<tr>
<td>Journal of Genetic Syndromes &amp; Gene Therapy</td>
<td>J Genet Syndr Gene Ther</td>
<td>1.44</td>
<td>-</td>
</tr>
<tr>
<td>Hydrology: Current Research</td>
<td>Hydrolog Res</td>
<td>0.38</td>
<td>4.93</td>
</tr>
<tr>
<td>Journal of Molecular Biomarkers &amp; Diagnosis</td>
<td>J Mol Biomark Diagn</td>
<td>2.04</td>
<td>4.37</td>
</tr>
<tr>
<td>Journal of Microbial &amp; Biochemical Technology</td>
<td>J Microbial Biochem Technol</td>
<td>2.04</td>
<td>5.51</td>
</tr>
<tr>
<td>Journal of Neurology &amp; Neurophysiology</td>
<td>J Neuro Neurophysiol</td>
<td>0.83</td>
<td>-</td>
</tr>
<tr>
<td>Journal of Nanoscience &amp; Nanobiotechnology</td>
<td>J Nanoscience Nanobiotech</td>
<td>5.72</td>
<td>4.04</td>
</tr>
<tr>
<td>Journal of Proteomics &amp; Bioinformatics</td>
<td>J Proteomics Bioinform</td>
<td>2.22</td>
<td>9</td>
</tr>
<tr>
<td>Pharmaceutica Analytica Acta</td>
<td>Pharmaceut Acta</td>
<td>1.4</td>
<td>5.33</td>
</tr>
<tr>
<td>Journal of Pharmacogenetics &amp; Pharmacoproteomics</td>
<td>J Pharmacogenetics Pharmaco</td>
<td>1.3</td>
<td>4.71</td>
</tr>
<tr>
<td>Journal of Plant Pathology &amp; Microbiology</td>
<td>J Plant Pathol Microb</td>
<td>0.42</td>
<td>4.54</td>
</tr>
<tr>
<td>Journal of Thermodynamics &amp; Catalysis</td>
<td>J Thermodynam Catal</td>
<td>0.14</td>
<td>-</td>
</tr>
<tr>
<td>Journal of Tissue Science &amp; Engineering</td>
<td>J Tissue Sci Eng</td>
<td>2.17</td>
<td>4.88</td>
</tr>
<tr>
<td>Journal of Vaccines &amp; Vaccination</td>
<td>J Vaccines Vaccin</td>
<td>1.73</td>
<td>6.26</td>
</tr>
<tr>
<td>Journal of Veterinary Science &amp; Technology</td>
<td>J Vet Sci Technol</td>
<td>4.22</td>
<td>-</td>
</tr>
</tbody>
</table>

**Impact Factor Calculation:**

*Unofficial 2011 Impact Factors were established by dividing the number of articles published in 2010 and 2011 by that were cited in 2011 based on a search of the Google Scholar Citation Index database, by the number of articles published in the previous two years (2010 and 2011).

A = the number of times, articles published in 2010 and 2011, were cited by indexed journals during 2011

B = the total number of "citable items" published by that journal in 2010 and 2011.

Impact Factor (IF) = A/B

(Ref: http://en.wikipedia.org/wiki/Impact_factor)

Index Copernicus Value Calculation: http://journals.indexcopernicus.com/info.php*
2nd World Congress on
Cell Science & Stem Cell Research
November 12-14, 2012  Hilton San Antonio Airport, USA

Supporting Journals
Cell being the smallest part of every organism, is a building block of life. Cell therapies often focus on the treatment of hereditary diseases, with methods of gene therapy. The journal describes biology of a cell and the process of pioneering new cells into a tissue in order to negotiate a disease.

http://www.amicsonline.org/jcst/home.php

Editors & Editorial Board

- **Editor-in-Chief**
  - George Perry
  - University of Texas
  - USA

- **Executive Editor**
  - Manjunath N Swamy
  - Texas Tech University
  - USA

- **Executive Editor**
  - Rakesh K Srivastava
  - University of Kansas
  - USA

- **Alunru S Reddi**
  - UMDNJ-New Jersey Medical School, USA

- **Nam H Dang**
  - University of Florida
  - USA

- **Graça D Almeida-Farah**
  - University of Nevada
  - USA

- **Bo Lu**
  - Vanderbilt University
  - USA

- **Jayanthi Panyam**
  - University of Minnesota
  - USA

- **Sha-Jun (Jim) Du**
  - University of Maryland
  - USA

- **Philip Ng**
  - Baylor College of Medicine
  - USA

Porunelloor A Mathew, University of North Texas, USA
Shong Song, University of Florida, USA
Andrew J Bean, University of Texas Medical School, USA
Shouwei Han, Emory University, USA
Shengwen Calvin Li, University of California USA
Sharon DeMorow, Texas A&M Health Science Center, USA
John S Kuo, University of Wisconsin, USA
Mustapha Kandouz, Wayne State University USA
Christophe Eges, Tufts University, USA
Glória Morris, Mount Sinai Hospital of Queens USA
V. Krishnan Ramanujan, Cedars-Sinai Medical Center, USA
Patricia I Meneses, Rosalind Franklin University USA
Piyali Dasgupta, Marshall University, USA
Xiong Li, University of Maine, USA
Rajasinh Johnson, University of Kansas, USA
Amit Singh, University of Dayton, USA
Dan Jia D D S, University of Arkansas, USA
Deng W, University of California, USA
Katsuyuki Hamada, Kyushu University, Japan
Hans Peter Hauber, Research Center Borstel, Germany
Ken Hayashi, Keio University, Japan
Zareen Amtul, University of Western Ontario, Canada
Giovanni Francese, University of Palermo, Italy
Tinghua Cao, Therakos Inc, USA
Sabine Specht, University Hospital Bonn, Germany
Yiqiang Zhang, Beckman Research Institute, USA
Zuzana Valaskova, Comenius University, Slovak

Vasili Arkica, University Hospital, Central Europe
Sang-Hyuk Chung, University of Houston, USA
David Misek, University of Michigan, USA
Jian Zhang, University of Maryland, USA
Lakkreddi Alagarsamy, Northwestern University, USA
Faris O B Aenzi, Al-Khair University, Saudi Arabia
Wei-Chiao Chang, Kaohsiung Medical University, Taiwan
Hansen Wang, University of Toronto, Canada
Antoine de Morrèe, University of Stanford, USA
<table>
<thead>
<tr>
<th>Handling editor</th>
<th>Title of the special issue</th>
<th>Logo of the University / Institute</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Radiotherapy</strong></td>
<td>V Krishnan Ramanujan Assistant Professor Department of Surgery Cedars-Sinai Medical Center Los Angeles, CA, USA Tel: +1-310-423-7666 Fax: +1-310-423-7707</td>
<td></td>
</tr>
<tr>
<td><strong>Cell Therapy: Clinical Trials</strong></td>
<td>Nam H Dang Professor Division of Hematology/Oncology University of Florida Gainesville, USA Tel: +1-352-273-9103</td>
<td></td>
</tr>
<tr>
<td><strong>Central Nervous System: Cell Therapy</strong></td>
<td>Alluru S Reddi Professor Department of Medicine UMDNJ-New Jersey Medical School New Jersey, USA Tel: +1-973-972-6052</td>
<td></td>
</tr>
<tr>
<td><strong>Gene Therapy: Somatic &amp; Germine</strong></td>
<td>Sha-Jun (Jim) Du Associate Professor Department of Biochemistry and Molecular Biology University of Maryland, USA Tel: +1-410-234-8854 Fax: +1-410-234-8996</td>
<td></td>
</tr>
<tr>
<td><strong>Cell-based Therapies of Blood Diseases: Malignant and Non-malignant</strong></td>
<td>Shengwen Calvin Li Adjunct Professor &amp; Senior Scientist, Department of Neurology Research Laboratory University of California, USA Tel: +1-714-289-4954 Fax: +1-714-289-4351</td>
<td></td>
</tr>
<tr>
<td><strong>Autophagy</strong></td>
<td>Ken Hayashi Assistant Director Department of Otolaryngology Keio University Japan</td>
<td></td>
</tr>
<tr>
<td><strong>Cell-based Therapies of Blood Diseases: Malignant and Non-malignant</strong></td>
<td>Gloria Morris Assistant Professor Department of Medicine Mount Sinai Hospital of Queens, USA Tel: +1-570-342-3675</td>
<td></td>
</tr>
<tr>
<td><strong>Stem Cells: Reprogramming &amp; Therapy</strong></td>
<td>Rajasingh Johnson Assistant Professor Department of Medicine Cardiovascular Research Institute, University of Kansas Medical Center USA</td>
<td></td>
</tr>
<tr>
<td><strong>T-Cell: Biology and Therapy</strong></td>
<td>Tinghua Cao Senior Research Scientist Johnson &amp; Johnson, Baylor Institute for Immunology Research Center R&amp;D, USA Tel: +1-610-651-6748 Fax: +1-612-889-423</td>
<td></td>
</tr>
<tr>
<td><strong>Transplantation</strong></td>
<td>ShouWei Han Associate Professor Department of Hematology and Medical Oncology Emory University, USA Tel: +1-404-727-4523</td>
<td></td>
</tr>
<tr>
<td><strong>Cell Therapy</strong></td>
<td>Yiqiang Zhang Staff Scientist Department of Molecular Medicine, Beckman Research Institute City of Hope, USA</td>
<td></td>
</tr>
<tr>
<td><strong>Cancer Therapy</strong></td>
<td>Zareen Amtul Research Scientist Department of Anatomy and Cell Biology University of Western Ontario, London, ON N6A 5C1, Canada</td>
<td></td>
</tr>
</tbody>
</table>

**OMICS Group Inc.**
2360 Corporate Circle, Suite 400, Henderson, NV 89074-7722, USA
Ph: +1-888-843-8169, Fax: +1-650-618-1417
Toll Free: +1-800-218-8499, E-mail: contact.omics@omicsonline.org
Stem cells differ from other types of cells as they are unspecialized cells that are capable of differentiating into almost any type of specialized cells. Stem cells have the ability to replace the diseased and damaged tissue in the body without the risk of rejection and any side effects. Therapy performed using stem cells is termed as "Regenerative Medicine" and has many potential benefits in treating a wide variety of diseases and injuries. The journal is the major open access forum for translational research in stem cell therapies.

http://www.unicsonline.org/jscrt/home.php
<table>
<thead>
<tr>
<th>Handling Editor</th>
<th>Title of the Special Issue</th>
<th>Logo of the University / Institute</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiovascular Cell Therapy</strong></td>
<td>Rosalinda Madonna</td>
<td><img src="logo" alt="UTHealth" /></td>
</tr>
<tr>
<td>Assistant Professor</td>
<td>Cardiology Division</td>
<td>University of Texas, USA</td>
</tr>
<tr>
<td>Tel. +1-713-500-2319</td>
<td>Fax: +1-832-355-9333</td>
<td></td>
</tr>
<tr>
<td><strong>Cardiovascular Cell Therapy</strong></td>
<td>Martin Rodriguez-Porcel</td>
<td><img src="logo" alt="MAYO CLINIC" /></td>
</tr>
<tr>
<td>Assistant Professor</td>
<td>Division of Cardiovascular Diseases, Mayo Medical School</td>
<td>USA</td>
</tr>
<tr>
<td>Tel. +1-507-536-6426</td>
<td>Fax: +1-507-266-0299</td>
<td></td>
</tr>
<tr>
<td><strong>Embryonic and Induced Pluripotent Stem Cells</strong></td>
<td>Jianlong Wang</td>
<td><img src="logo" alt="Mount Sinai" /></td>
</tr>
<tr>
<td>Assistant Professor</td>
<td>Department of Developmental and Regenerative Biology, Mount Sinai School of Medicine</td>
<td>USA</td>
</tr>
<tr>
<td>Tel. +1-212-241-7425</td>
<td>Fax: +1-212-241-3518</td>
<td></td>
</tr>
<tr>
<td><strong>Cell Therapy for Neurological Disorders</strong></td>
<td>Pranela Rameshwar</td>
<td><img src="logo" alt="UMDNJ" /></td>
</tr>
<tr>
<td>Professor</td>
<td>Department of Medicine, Hematology/Oncology, UMDNJ-New Jersey Medical School</td>
<td>USA</td>
</tr>
<tr>
<td><strong>Transplantation Immunology</strong></td>
<td>Qing Ma</td>
<td><img src="logo" alt="Texas A&amp;M University" /></td>
</tr>
<tr>
<td>Associate Professor</td>
<td>Department of Stem Cell Transplantation and Cellular Therapy</td>
<td>University of Texas, USA</td>
</tr>
<tr>
<td><strong>Hematopoietic Stem Cell Transplantation</strong></td>
<td>Porras Luis F</td>
<td><img src="logo" alt="MAYO CLINIC" /></td>
</tr>
<tr>
<td>Assistant Professor, Director of the Blood and Marrow Program</td>
<td>Mayo Clinic Transplant Center, USA</td>
<td></td>
</tr>
<tr>
<td><strong>Cardiac Resident Stem Cells and Progenitors</strong></td>
<td>Vincenzo Lionetti</td>
<td><img src="logo" alt="University of Texas" /></td>
</tr>
<tr>
<td>Assistant Professor</td>
<td>Department of Physiology, Scuola Superiore Sant'Anna University, Italy</td>
<td></td>
</tr>
<tr>
<td>Tel. +39-050-315-2216</td>
<td>Fax: +39-050-315-2166</td>
<td></td>
</tr>
<tr>
<td><strong>Tissue Specific Stem Cells</strong></td>
<td>Morayma Reyes</td>
<td><img src="logo" alt="University of Washington" /></td>
</tr>
<tr>
<td>Assistant Professor</td>
<td>Department of Laboratory Medicine, University of Washington</td>
<td>USA</td>
</tr>
<tr>
<td>Tel. +1-206-616-5004</td>
<td>Fax: +1-206-897-1540</td>
<td></td>
</tr>
<tr>
<td><strong>Cell Therapy for Diabetes</strong></td>
<td>Ipsita Banerjee</td>
<td><img src="logo" alt="University of Pittsburgh" /></td>
</tr>
<tr>
<td>Assistant Professor</td>
<td>Department of Bioengineering, University of Pittsburgh</td>
<td>USA</td>
</tr>
<tr>
<td>Tel. +1-412-624-2071</td>
<td>Fax: +1-412-624-9639</td>
<td></td>
</tr>
<tr>
<td><strong>Cell Therapy for Diabetes</strong></td>
<td>Yong Zhao</td>
<td><img src="logo" alt="University of Illinois" /></td>
</tr>
<tr>
<td>Assistant Professor</td>
<td>Department of Medicine, University of Illinois, USA</td>
<td></td>
</tr>
<tr>
<td><strong>Muscle Stem Cells</strong></td>
<td>Aisushi Asakura</td>
<td><img src="logo" alt="University of Minnesota" /></td>
</tr>
<tr>
<td>Assistant Professor</td>
<td>Stem Cell Institute, University of Minnesota Medical School</td>
<td>USA</td>
</tr>
<tr>
<td>Tel. +1-612-625-9900</td>
<td>Fax: +1-612-625-7950</td>
<td></td>
</tr>
<tr>
<td><strong>Muscle Stem Cells</strong></td>
<td>Stefano Biessi</td>
<td><img src="logo" alt="Stanford University" /></td>
</tr>
<tr>
<td>Post-doctoral Research Associate, Department of Neurology and Neurosurgical Sciences</td>
<td>Stanford University, USA</td>
<td></td>
</tr>
</tbody>
</table>

Journal of Stem Cell Research & Therapy: Open Access using online manuscript submission, review and tracking systems of Editorial Manager® for quality and quick review processing. Submit your manuscript at [http://www.editorialmanager.com/lifesciences](http://www.editorialmanager.com/lifesciences) or mail to editor@jomicsonline.org.
Upcoming Conferences
### Pharmaceutical

3rd International Conference and Exhibition on Analytical & Bioanalytical Techniques  
November 22-24, 2012 Hyderabad International Convention Centre, India

International Conference and Exhibition on Cosmeticology & Cosmetics  
November 23-24, 2012 Hyderabad International Convention Centre, India

2nd International Conference on Pharmaceutical Regulatory Affairs  
November 23-24, 2012 Hyderabad International Convention Centre, India

International Summit on GMP & GCP: USA, Europe, Japan, Asia Pacific  
December 3-5, 2012 DoubleTree by Hilton Philadelphia Center City, USA

International Conference on QA, QC and Validation  
December 3-5, 2012 DoubleTree by Hilton Philadelphia Center City, USA

3rd International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems  
April 8-10, 2013 Hilton Chicago/Northbrook, USA

4th World Congress on Bioavailability and Bioequivalence: Pharmaceutical R & D Summit  
May 20-22, 2013 Beijing, China

2nd International Conference and Exhibition on Biowavers & Biosimilars  
September 23-25, 2013 Kaneue/Michigan, USA

QC, QA and Validation  
October 15-17, 2013 Crowne Plaza, CA, USA

2nd International Expo and Conference on Analytix and HPLC  
October 15-17, 2013 Crowne Plaza, CA, USA

2nd Annual Pharmacovigilence & Clinical Trials Conference  
October 21-23, 2013 Marriott, India

International Conference and Exhibition on Pharmaceuticals & Phytochemistry  
October 21-23, 2013 Marriott, India

2nd International Summit on Toxicology & Applied Pharmacology  
November 4-6, 2013 Crowne Plaza, California, USA

International Summit on Clinical Pharmacy & Dispensing  
November 18-20, 2013 Hilton San Antonio Airport, Texas, USA

### Computer Science

International Conference & Workshop on Ethical Hacking and Cyber Security  
December 9-11, 2013 India

International Conference on Global Networking and Telecommunications  
December 9-11, 2013 India

International Conference on Computer Science/Software & Advanced Information Technology  
September 23-25, 2013 Marriott, India

2nd International Conference and Exhibition on In silico & QSAR (CADD)  
September 4-6, 2013 Crowne Plaza, Miami, Florida

### Medical Sciences

International Conference on Genetic Syndromes & Gene Therapy  
November 19-21, 2012 Hilton San Antonio Airport, USA

International Conference on Anesthesia & Perioperative Care  
November 26-28, 2012 Hilton San Antonio Airport, USA

International Conference and Exhibition on Surgery & Transplantation  
November 26-28, 2012 Hilton San Antonio Airport, USA

International Conference on Hair Transplantation & Trichology  
November 26-28, 2012 Hilton San Antonio Airport, USA

International Conference and Exhibition on Obesity & Weight Management  
December 23-24, 2012 DoubleTree by Hilton Philadelphia, USA

2nd International Conference on Gastroenterology & Urology  
June 10-12, 2013 Hilton Chicago/Northbrook, USA

2nd International Conference and Exhibition on Nutritional Science & Therapy  
July 15-17, 2013 DoubleTree by Hilton Philadelphia Center City, USA

2nd International Conference and Exhibition on Addiction Research & Therapy  
July 22-24, 2013 Embassy Suites Las Vegas, USA

2nd International Conference and Exhibition on Nephrology & Therapeutics  
July 29-31, 2013 Embassy Suites Las Vegas, USA

2nd International Conference on Translational Medicine  
August 5-7, 2013 Holiday Inn Chicago-Northshore, USA

International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics  
Holiday Inn Chicago-Northshore, USA

4th World Congress on Diabetes & Metabolism  
August 14-16, 2013 Holiday Inn Chicago-Northshore, USA

International Conference on Dental & Oral Health  
August 19-21, 2013 Embassy Suites Las Vegas, USA

2nd International Conference and Exhibition on Orthopedics & Rheumatology  
August 19-21, 2013 Embassy Suites Las Vegas, USA

International Conference and Exhibition on Physical Medicine & Rehabilitation  
August 19-21, 2013 Embassy Suites Las Vegas, USA

World Congress on Endocrinology  
August 26-28, 2013 Double tree by Hilton, Raleigh NC, USA

International Conference and Exhibition on Cognitive, Behavioral Psychology & Psychotherapy  
August 27-28, 2013 Double tree by Hilton, Raleigh NC, USA

International Conference on Gynecology & Women's Health  
September 16-18, 2013 Hampton Inn Tropicana, Las Vegas, USA

International Conference on Sexology & Sexual Medicine  
September 16-18, 2013 Hampton Inn Tropicana, Las Vegas, USA

3rd International Conference on Pediatrics and Neonatology  
September 16-18, 2013 Hampton Inn Tropicana, Las Vegas, USA

2nd International Conference on Pulmonary & Respiratory Medicine  
September 30-October 2, 2013 Hilton San Antonio Airport, Texas, USA

2nd International Conference on Otolaryngology  
September 30-October 2, 2013 Hilton San Antonio Airport, Texas, USA

International Conference on Hematology & Blood Disorders  
October 15-17, 2013 Hampton Inn Tropicana, Las Vegas, USA

International Conference and Exhibition on Traditional & Alternative Medicine  
December 9-11, 2013 Marriott, India

International Conference on Nursing & Emergency Medicine  
December 2-4, 2013 Hampton Inn Tropicana, Las Vegas, USA

World Symposium on Autism, Parkinson's Disease & Alzheimer's Disease  
December 2-4, 2013 Hampton Inn Tropicana, Las Vegas, USA

### Clinical

International Toxicology Summit & Expo  
November 28-29, 2012 Hilton San Antonio Airport, USA

3rd International Conference on Clinical & Experimental Cardiology  
April 15-17, 2013 Hilton Chicago/Northbrook, USA

3rd International Conference on Clinical & Experimental Dermatology  
April 15-17, 2013 Hilton Chicago/Northbrook, USA

3rd International Conference on Clinical & Experimental Ophthalmology  
April 15-17, 2013 Hilton Chicago/Northbrook, USA

2nd International Conference on Occupational Health & Safety  
May 20-22, 2013 Beijing, China

2nd International Conference and Exhibition on Neurology & Therapeutics  
June 17-19, 2013 Hilton Chicago/Northbrook, USA

4th International Conference on Biomarkers & Clinical Research  
July 16-17, 2013 DoubleTree by Hilton Philadelphia Center City, USA

3rd International Conference on Vaccines & Vaccination  
July 29-31, 2013 Embassy Suites Las Vegas, USA

2nd International Conference and Exhibition on Pathology  
August 5-7, 2013 Embassy Suites Las Vegas, USA

2nd International Conference on Emerging Cell Therapies  
August 12-14, 2013 Marriott, Singapore

International Conference on Molecular Epidemiology and Evolutionary Genetics  
August 21-23, 2013 Crowne Plaza, Miami, Florida, USA
**Life Sciences**

- International Conference and Exhibition on Food Processing & Technology™
  - July 15-17, 2013 Marriott, Singapore
- International Conference on Animal & Dairy Sciences
  - July 23-24, 2013 Embassy Suites Las Vegas, USA
- International Conference on Integrative Biology Summit
  - August 5-7, 2013 Embassy Suites Las Vegas, USA
- International Conference and Symposium on Genetic Engineering & Genetically Modified Organisms
  - August 12-14, 2013 DoubleTree by Hilton, Raleigh NC, USA
- International Conference on Tissue Science & Engineering
  - September 4-6, 2013 Crowne Plaza, Miami, Florida, USA
- International Conference on Agricultural & Horticultural Sciences
  - September 23-25, 2013 Marriott, India
- World Congress on Bionotechnology
  - September 23-25, 2013 Kansas/Michigan, USA
- International Conference on Entomology
  - September 30-October 2, 2013 Hilton San Antonio Airport, Texas, USA
- International Conference on Fermentation Technology, Bio Processing & Cell Culture
  - October 28-30, 2013 Kansas, USA
- International Congress on Bacteriology & Infectious Diseases
  - November 20-22, 2013 Hilton Pikes Villa, Baltimore, USA

**Environmental**

- International Conference on Earth Science & Climate Change
  - July 22-24, 2013 Embassy Suites Las Vegas, USA
- International Conference on Biodiversity & Sustainable Energy Development
  - August 12-14, 2013 DoubleTree by Hilton, Raleigh NC, USA
- International Conference on Aquatic and Marine Biology (Oceanography)
  - August 21-23, 2013 Crowne Plaza, Miami, Florida, USA
- International Conference on Managing Environmental Hazards and Natural Disasters
  - August 21-23, 2013 Crowne Plaza, Miami, Florida, USA
- International Conference on Hydrology and Groundwater Expo
  - August 26-28, 2013 DoubleTree by Hilton, Raleigh NC, USA
- International Conference on Archaeology & Anthropology
  - November 18-20, 2013 Hilton San Antonio Airport, Texas, USA

**OMICS**

- 2nd International Conference and Exhibition on Metabolomics & Systems Biology
  - April 8-10, 2013 Hilton Chicago/Northbrook, USA
- 3rd International Conference on Proteomics & Bioinformatics
  - July 15-17, 2013 DoubleTree by Hilton Philadelphia Center City, USA
- International Conference on Omics Studies
  - September 4-6, 2013 Crowne Plaza, Miami, Florida, USA
- International Conference on Functional & Comparative Genomics
  - November 13-14, 2013 Holiday Inn Chicago, NorthShore
2nd World Congress on
Cell Science & Stem Cell Research
November 12-14, 2012  Hilton San Antonio Airport, USA

Relevant Conferences
International Conference on
Genetic Syndromes & Gene Therapy
November 19-21, 2012 Hilton San Antonio Airport, USA
Theme: “Building on Clinical Progress & Exploring Advances in Gene Therapy”

The International Conference on Genetic Syndromes & Gene Therapy is a unique platform to advance knowledge, awareness and education by amalgamating Science and Technology using the saner applications of clinical & diagnostic therapeutic strategies in confronting various issues related to Genetics and Genetic disorders.

Scientific Tracks

Track 1: Gene Therapy
Track 1-1 Novel technologies for gene transfer
Track 1-2 Gene transfer to induce cellular reprogramming
Track 1-3 Molecular cloning and expression of a new gene
Track 1-4 Gene expression in mononuclear cells
Track 1-5 Transfer and expression of genes in humans

Track 2: Viral Vectors for Gene Therapy
Track 2-1 Immune response to viral vectors
Track 2-2 Viral entry and nuclear translocation
Track 2-3 Host cell response to viral infection
Track 2-4 Innate & adaptive immune response to viral infection
Track 2-5 Approaches to blocking the immune response to viral infection
Track 2-6 Suppression & stimulation of the immune response by gene transfer
Track 2-7 Improvements in vector development

Track 3: Molecular Therapy
Track 3-1 Novel anticoagulant therapy
Track 3-2 Bridging therapy
Track 3-3 Biomarkers of endocrine therapy
Track 3-4 Therapeutic cancer vaccines
Track 3-5 DNA vaccination for treatment of cancer
Track 3-6 Targeted molecular therapies

Track 4: Diagnosing Genetic Syndromes
Track 4-1 Molecular techniques
Track 4-2 FSH analysis
Track 4-3 Mental retardation syndromes database
Track 4-4 Neonatal screening
Track 4-5 Early genetic amniocentesis
Track 4-6 Chorionic villus sampling
Track 4-7 Gene silencing

Track 5: Gene Therapy in the Retina
Track 5-1 RNA based therapeutics for retinal degenerative disorders
Track 5-2 Vector based strategies for retinal gene therapies
Track 5-3 Gene therapy for retinal degenerative

Track 6: Developmental Genetics
Track 6-1 Immunogenetics
Track 6-2 Neurogenetics
Track 6-3 Evolution and population genetics
Track 6-4 Medical genetics and heredity counseling
Track 6-5 Human genetic disorders
Track 6-6 Human embryology & developmental analysis of human genetics

Track 7: Genetic Disorders
Track 7-1 Single gene disorder
Track 7-2 Multifactorial and polygenic (complex) disorders
Track 7-3 Prognosis and treatment of genetic disorders
Track 7-4 Genetic syndrome associated with glucose intolerance
Track 7-5 Hereditary disorders

Track 8: Gene Therapy for Autoimmune Diseases & Epigenetics
Track 8-1 Hereditary multiple exostoses
Track 8-2 Adenomatous polyposis
Track 8-3 Genomic imprinting and related disorders
Track 8-4 Translational epigenetic observations
Track 8-5 Cancer and developmental abnormalities computational epigenetics
Track 8-6 Induced pluripotent stem cells and potential therapies

Track 9: Applied Molecular Biology
Track 9-1 Genetic variation and diversity
Track 9-2 Molecular evolution
Track 9-3 Genetic diseases caused by alterations of RBP or RNA sequence
Track 9-4 RNAi mechanisms and miRNAs

Track 10: Current Strategies in Gene Therapy
Track 10-1 Recombinant DNA and gene transfer
Track 10-2 Human gene therapy and the role of the food and drug administration
Track 10-3 Genetics & Oncology
Track 10-4 Hereditary neuropathy
Track 10-5 Genome stability and DNA repair

Track 11: Clinical Genetics
Track 11-1 Pharmacogenetics
Track 11-2 Neurogenetics
Track 11-3 Community genetics
Track 11-4 Molecular cytogenetics
Track 11-5 Reproductive genetics
Track 11-6 Gene expression profiling

Track 12: Cancer Genetics
Track 12-1 Oncogenes
Track 12-2 Tumor suppressor genes
Track 12-3 Viruses & human cancer
Track 12-4 Genetics & toxicity
Track 12-5 Gene silencing & genome imprinting
Track 12-6 RNA interference

Track 13: Genetic Mapping Methods / Linkage analysis
Track 13-1 Cloning and expression systems
Track 13-2 Molecular genetic processes
Track 13-3 Mobile genetic elements
Track 13-4 Cellular and organismal genetic processes
Track 13-5 Ethical, legal and social implication of genetics
OMICS Group is organizing Gene Therapy-2012 with the overwhelming support from more than 200 Editorial Board Members of related journals, that includes Journal of Genetic Syndromes & Gene Therapy, Hereditary Genetics and Human Genetics & Embryology

### Editorial Board Members of Supporting Journals

- **Kenneth Blum**  
  Professor  
  Department of Psychiatry  
  University of Florida, USA  
  Tel: 619-890-2167  
  Fax: 352-273-8342

- **Yiqiang Cai**  
  Associate professor  
  Department of Internal Medicine  
  Yale University School of Medicine  
  USA  
  Tel: 203-737-2941

- **Roland W. Herzog**  
  Professor  
  Department of Pediatrics  
  Microbiology and Molecular Genetics  
  University of Florida, USA  
  Tel: 352-273-8113  
  Fax: 352-273-8342

- **Irinide Sharina**  
  Assistant professor  
  Department of Internal Medicine  
  University of Texas Medical School  
  USA  
  Tel: 713-486-2480

- **Kenneth Lundstrom**  
  CEO  
  Fion Therapeutics Rue des Remparts  
  Switzerland  
  Tel: 179-776-6351

- **Brittney Shear Herbert**  
  Associate Professor  
  Department of Medical and Molecular Genetics  
  Indiana University School of Medicine  
  USA  
  Tel: 317-278-6147  
  Fax: 317-274-1069

- **Jack M. Sullivan**  
  Associate Professor  
  The Ira G. Ross Eye Institute  
  University at Buffalo-SUNY, USA  
  Tel: 716-862-6583  
  Fax: 716-862-6524

- **Van Meir EG**  
  Professor  
  Department of Neurosurgery and Hematology/Oncology  
  Emory University School of Medicine USA  
  Tel: 404-772-5006

- **Prem Arora**  
  Paediatrics Advisory Member  
  Wayne State University  
  Children's Hospital of Michigan, USA  
  Tel: 313-745-4000

- **Dawn E. Post**  
  SUNY Upstate Medical University, USA

- **Kirk J. McManus**  
  University of Manitoba, USA

- **William J. Rowe**  
  Fellow British Interplanetary Society, UK

- **Chatthai Tuyapiratana**  
  Chiang Mai University, Thailand

- **Aldo T Krajin**  
  Professor  
  Department of Genetics  
  Washington University, USA  
  Tel: 314-362-2498  
  Fax: 314-362-2227

- **OMICS Group**

### Confirmed Speakers Including

- **Ricki Lewis**  
  American Society of Human Genetics, USA

- **Prem Arora**  
  Wayne State University, USA

- **Yiqiang Cai**  
  Yale University School of Medicine, USA

- **Kenneth Lundstrom**  
  Pan Therapeutics Rue des Remparts, Switzerland

- **Juan Ren**  
  Xian Jiao Tong University, China

- **Jianzhong Su**  
  Harbin Medical University, China

### Join your Peers @ Gene Therapy-2012

- Are you interested in organizing a track?
- Organizing a small symposium at this venue?
- Organizing a small workshop at this conference?
- Deliver a speech?
- Present a poster/abstract presentation?
- Sponsor the event?
- Exhibit at the event?
- Participate in B2B meeting?

Please contact: genetherapy2012@omicsonline.com  
http://omicsonline.org/genetherapy2012

### Editors

- Journal of Genetic Syndromes & Gene Therapy  
- Hereditary Genetics  
- Human Genetics & Embryology

### Hosting Organization

OMICS Group Inc.  
2360 Corporate Circle, Suite 400, Henderson, NV 89074-7722, USA  
Phone: +1-888-843-8169, Fax: +1-850-618-1417  
Toll Free: +1-800-216-6409  
Email: contact.omics@omicsonline.org
3rd World Congress on Cancer Science & Therapy

October 21-23, 2013 California, USA

Theme: “Innovations and Novel Therapeutic strategies in Cancer Science”

OMICS Group is delighted to invite you to attend the 3rd World Congress on Cancer Science & Therapy during October 21-23, 2013 at California, USA.

3rd World Congress on Cancer Science & Therapy serves as a reunion land for scientists in the area of cancer research. This Conference aims to bring together academic scientists, leading engineers, industry researchers and scholars to exchange and share their experiences and research results about all aspects of Cancer Science and therapy, and discuss the practical challenges encountered and the solutions adopted.

The scientific program will include workshops, symposia and poster sessions on a wide range of Cancer Science topics. The conference will also feature a showcase of exhibitors for you to explore. Leading oncologists will descend upon the City to share and examine innovative scientific breakthroughs in cancer science from basic science to clinical research.

The previous two conferences on Cancer Science, which were held at Las Vegas, USA and San Anonio, USA, have explained Novel Approaches in Cancer Research & Therapy and Emerging Trends in Cancer Science. The programme was a rich mix of formats ranging from oral sessions featuring many well-known and thought provoking key speakers to intense and highly interactive discussion sessions. The scientific program also helped to pave a way to gather visionaries through the research talks and presentations and put forward many thought provoking strategies in Cancer Science and Therapy.

Now it is the time for the 3rd World Congress on Cancer Science & Therapy to share the Knowledge and Innovations and Novel Therapeutic strategies in Cancer Science which will be held in California, USA.

Scientific Tracks

Track 1: Cancer Therapy and Clinical Cancer Research
Track 1-1 Cancer: Gene expression & protein profiling, Surgery & laparoscopy
Track 1-2 Radiotherapy & chemotherapy
Track 1-3 Hormone replacement therapy
Track 1-4 Molecular-targeted therapies
Track 1-5 Clinical medicine & targeting anti cancer drugs
Track 1-6 Therapeutic agents in cancer
Track 1-7 Clinical research in cancer immunology
Track 1-8 Anticancer gene therapy and stem cells therapy

Track 2: Cancer Cell Biology, Diagnostic and Prognostic Cancer Biomarkers
Track 2-1 Cancer stem cells and metastatic growth
Track 2-2 Cell signaling and membrane proteins: Inflammation and inflammatory factors in cancer development
Track 2-3 Metastatic cell growth & adhesion: Apoptosis & cell division
Track 2-4 Biomarkers in cancer therapy & molecular diagnostics
Track 2-5 DNA methylation and mutation based biomarkers, prognostic biomarkers
Track 2-6 Biomarkers based on cancer types

Track 3: Organ-Specific Cancers, Cancer Genetics, Drug Development & Diagnostics
Track 3-1 Breast cancer, lung cancer, brain cancer, skin cancer and sarcomas
Track 3-2 Liver, prostate, kidney, ovarian and cervical cancer
Track 3-3 Blood, lung & leukemia cancer
Track 3-4 Bone & thyroid cancer
Track 3-5 Gastrointestinal & colorectal cancer

Track 4: Carcinogenesis & Mutagenesis and OMICS in Cancer Research
Track 4-1 Metabolism of carcinogens
Track 4-2 Biological & external factors for carcinogenesis
Track 4-3 Cancer Research: Clinical & experimental oncology
Track 4-4 Cancer cell lines: Genomics & proteomics

Track 5: Advances in Cancer Detection, Imaging, Management & Prevention
Track 5-1 Biomarkers in cancer detection
Track 5-2 Diet & physical exercise
Track 5-3 Chemoprevention
Track 5-4 Environmental factors
Track 5-5 Chemotherapy of cancers

Track 6: Anti-Cancer Drug Discovery and Development
Track 6-1 New cancer biomarkers as drug targets
Track 6-2 Anticancer drugs targeting protein kinase inhibitors
Track 6-3 Anticancer drugs targeting Tumor Necrosis Factor (TNF) and chemokine receptors
Track 6-4 Antibodies for cancer therapy
Track 6-5 Anticancer drugs targeting signalling pathways and regulators
Track 6-6 Anticancer drugs targeting GPCR, Nuclear receptor inhibitors and hormonal therapies
Track 6-7 Apoptotic inducers, targeting apoptosis signaling pathways and their mediators

Track 7: Innovation Technologies in Cancer Research
Track 7-1 Protein chips, tissue chips, lab-on-chip and microarray
Track 7-2 Proteomics, genomics and other Omics in cancer research
Track 7-3 PET, cancer digital imaging and image-guided technologies
Track 7-4 Anticancer drug resistance and new molecule searching
Track 7-5 Bioinformatics, drug design and computer aided anticancer drug discovery

Track 8: Tumor Science
Track 8-1 Tumor virology
Track 8-2 Tumor immunology and immunotherapy
Track 8-3 Tumor microenvironment and research
Track 8-4 Tumor varieties: Benign, pre-malignant, malignant
Track 8-5 Tumor progression, invasion and metastasis

Track 9: Industrial Leaders in Cancer Research
Past Conference Report (Cancer Science-2012)

2nd World Congress on Cancer Science & Therapy, hosted by the OMICS Group was held on September 10-12, 2012 in Hilton San Antonio Airport, USA. Generous response and active participation received from the Researchers, Scientists from cancer research institutes, Government Organizations, Principal Investigators from NCI & NIH and Editorial Board Members of OMICS Group helped in making this meeting an ostentatious success.

Keynote presentations of Dr. Sudhakar Akul Yakkanti, Dr. Dan A. Dixon, Dr. Alexei G Basnakian, Dr. Homer S Black and Dr. Sophia Ran was very prolific to the scientific community and they lifted up solutions and illustrated a way on the theme "Emerging trends in Cancer Science and Therapy."

Especially on the scientific sessions like Organ-Specific Cancers, Cancer Cell Biology, Cancer Genetics: Cancer Therapy, Carcinogenesis & Mutagenesis, Diagnostic and Prognostic Cancer Biomarkers, we found more energetic contribution from scientists, researchers and principal investigators. Presentations during these sessions were excellent. It established a new prospect and hopes on ongoing projects in Cancer Science & Therapy.

With the huge optimistic response from scientific fraternity, industries, renowned personalities and editorial board members of OMICS Group across the world, we would like to announce 3rd World Congress on Cancer Science & Therapy during December 2-4, 2013 at California, USA.

Join your Peers @ Cancer Science- 2013

- Are you interested in organizing a track?
- Organize a small symposium at this venue?
- Organizing a small workshop at this conference?
- Deliver a speech?
- Present a poster/oral presentation?
- Sponsor the event?
- Exhibit at the event?
- Participate in B2B meeting?

Please contact: cancerscience2013@omicsgroup.org
http://www.omicsgroup.com/conferences/cancer-science-therapy-2013/

Editors
Journal of Cancer Science & Therapy
Journal of Carcinogenesis & Mutagenesis and Chemotherapy: Open Access

Hosting Organization
OMICS Group Inc.
2360 Corporate Circle, Suite 400, Henderson, NV 89074-7722, USA
Phone: +1-888-845-6169, Fax: +1-850-618-1417
Toll Free: +1-800-216-0499
Email: contact.omics@omicsonline.org
2nd International Conference on
Emerging Cell Therapies
August 12-14, 2013 Raleigh, USA

Theme: “Evolving Technology in Cell Therapy and its Future Perspectives”

OMICs Group invites all the participants across the globe to attend the 2nd International Conference on Emerging Cell Therapies to be held during August 12-14, 2013 at Raleigh, USA.

Cell Therapy-2013 is a remarkable event which brings together a unique and International mix of leading Universities and cell therapy institutions making the Congress a perfect platform to share experience and which paves a way to gather visionaries through the research talks and presentations and put forward many thought provoking strategies in emerging cell therapies.

Scientific Tracks

Track 1: Cell Therapy - Potential Applications
Track 1-1 Molecular therapy
Track 1-2 Ocular therapy
Track 1-3 Neuro therapy for neurological diseases
Track 1-4 Cardiac cell therapy
Track 1-5 Cell therapies for renal failure
Track 1-6 RNA therapeutics

Track 2: Stem Cell Therapies
Track 2-1 Molecular basis of pluripotency
Track 2-2 Bone marrow stem cells as therapy
Track 2-3 Current views of the embryonic & neural stem cells
Track 2-4 Stem cell therapy for genetic disorders
Track 2-5 Targeting stem cells for therapeutic benefits
Track 2-6 Transplantation technologies in stem cell therapy

Track 3: Cellular Therapies
Track 3-1 Cell replacement therapy
Track 3-2 Potential uses of defined cell populations
Track 3-3 Reprogramming cell fate
Track 3-4 Role of molecular markers in therapies
Track 3-5 Target tissues and routes of delivery
Track 3-6 Causes of regenerative failure

Track 4: Cancer Therapies
Track 4-1 Stem cells & cancer treatments
Track 4-2 Characteristics of cancer cells
Track 4-3 Cell cycle and oncology
Track 4-4 Modern approaches in molecular cancer therapeutics
Track 4-5 Genomics & cancer drug resistance
Track 4-6 Targeted cancer therapy
Track 4-7 Genetically engineered cancer vaccines
Track 4-8 Challenges & risks of cancer gene therapy

Track 5: Clinical Trials & Research in Cell Therapies
Track 5-1 Principles of gene therapy & clinical gene therapy
Track 5-2 Animal & human trials of engineered tissues
Track 5-3 Emerging clinical aspects of stem cell therapy
Track 5-4 Pharmacogenomics in cell therapy
Track 5-5 Clinical trial design and analysis
Track 5-6 Alternative lab models for cell therapy applications

Track 6: Nanotechnology in Cell Therapies
Track 6-1 Nano methods to target cancer cells
Track 6-2 Nano-microfluidics in cell therapy
Track 6-3 Nano materials and nano engineering
Track 6-4 Pros and cons of molecular manufacturing
Track 6-5 Nanovaccines

Track 7: Bioengineering in Cell Therapeutics
Track 7-1 Biomedical engineering
Track 7-2 Developing new probes for tissue targeting
Track 7-3 Therapeutic bioengineering
Track 7-4 Cellular mechanobiology
Track 7-5 Tissue engineering from own stem cells
Track 7-6 Current understanding & challenges in bioprocessing
Track 7-7 Bioengineering for medical diagnostics and imaging

Track 8: Immunotherapy
Track 8-1 Cell based immunotherapy
Track 8-2 Cancers of immune cells
Track 8-3 New cell therapies for allergies
Track 8-4 Cell based immunosuppression in transplantation
Track 8-5 Tumour cells evade/defeat immune system

Track 9: Regulatory & Ethical Issues of Cell Therapy
Track 9-1 Commercialization strategy
Track 9-2 Applications of cell therapy — from bench to bedside
Track 9-3 Cell therapy in future medicine
Track 9-4 Ethics involved in human stem cells
Track 9-5 Logistics in preparing lab models for cell therapy applications
Track 9-6 Manufacturing of cell therapy products and marketing guidelines
Track 9-7 Innovative therapeutic technologies
Track 9-8 FDA & EMA guidelines
Cell Therapy-2012 Report

International Conference on Emerging Cell Therapies, held during October 1-3, 2012 at DoubleTree by Hilton Chicago-North Shore, USA aimed to discuss the evolving "Evolving Technology in Cell Therapy and its Future Perspectives".

The zealous participation received from Editorial Board Members of OMICS Group Journals as well as from the researchers & scientists from various clinical research institutes, government organizations and companies related to Molecular Biology and Pharma helped in making this meeting a grand success.

Conference highlighted the following topics:
- Cell Therapy- Potential Applications
- Stem Cell Therapies
- Cellular Therapies
- Cancer Therapies
- Clinical Trials & Research in Cell Therapies
- Nanotechnology in Cell Therapies
- Bioengineering in Cell Therapeutics
- Regulatory & Ethical Issues of Cell Therapy
- Current Research & Future Perspectives on Cell Therapy

The grandeur of the event can be made out from the fact that more than 200 delegates representing 30 countries from different corners of the world became a part of it.

The conference was initiated with a series of invited lectures delivered by Honorable Guests and members of the keynote forum.

The list included Ivan N. Rich, CEO of HemoGenix Inc., USA, Robert W. Mays, Athersys Inc., USA; Kurt C Gunter, International Society for Cellular Therapy, Canada; Lee Buckler, Cell Therapy Group, USA and Tarek El-Bialy, University of Alberta, Canada. These presentations were very prolific to the scientific community and they lifted up solutions and illustrated a way on the theme "Evolving Technology in Cell Therapy and its Future Perspectives".

All accepted abstracts have been indexed in OMICS Group Cell Science & Therapy as a special issue.

With the huge optimistic response from scientific fraternity, industries, renowned personalities and editorial board members of OMICS Group across the world, we would like to announce the 2nd International Conference on Emerging Cell Therapies during August 12-14, 2013 at North Carolina, USA.

Join your Peers @ Cell Therapy-2013
- Are you interested in organizing a track?
- Organizing a small symposium at this venue?
- Organizing a small workshop at this conference?
- Deliver a speech?
- Present a poster/oral presentation?
- Sponsor the event?
- Exhibit at the event?
- Participate in B2B meeting?

Please contact: celltherapy2013@omicsgroup.info
http://www.omicsgroup.com/conferences/emerging-cell-therapies-2013/

Editors
Journal of Stem Cell Research & Therapy
Journal of Cancer Science & Therapy
Journal of Cell Science & Therapy

Hosting Organization
OMICS Group Inc.
2360 Corporate Circle, Suite 400, Henderson, NV 89074-7722, USA
Phone: +1-888-843-8169, Fax: +1-650-618-1417
Toll Free: +1-800-216-6499
Email: contact.omics@omicsonline.org
2nd World Congress on
Cell Science & Stem Cell Research
November 12-14, 2012  Hilton San Antonio Airport, USA

Keynote Forum
Old stem cells aren’t what they used to be

The idea of stem cells as medical therapy has become almost commonplace. Millions of individuals have stored stem cells in biobanks for future use, and tens of thousands have received stem cell transplants or infusions for regenerative medicine therapies. But often overlooked are everyday factors that may impair the utility of these stem cells, including stem cell age and donor health. There is increasing evidence that both factors can significantly impact the therapeutic potential of stem cells.

The hematopoietic stem cell is the best characterized of all stem cells. Weissman and others have shown significant functional changes with age, a finding confirmed upon analysis of cord blood transplant recipients. Similar findings have also been observed with neural stem cells. In terms of regenerative medicine, many are looking at mesenchymal stem cells (MSC). Numerous studies have indicated that MSCs isolated from older donors, as well as from patients with chronic disease conditions, are neither as prevalent (in terms of the number of cells in the sample) nor as potent as those isolated from younger, healthier donors. MSCs collected from elder donors seem less able to differentiate into the different cell types needed for tissue engineering, slower to proliferate and expand to numbers of cells that would allow for multiple treatments, and more prone to dying during culture and use.

Evidence that MSC quality declines with donor age warrants concern for cell based therapies. The ability of older stem cells to respond to injury may be compromised and could contribute to inferior tissue repair. We have observed such results when analyzing the effects of stem cell age in a chronic wound model. In addition, Shen et al at the University of Texas-Arlington found that aging female mice transplanted with young MSCs had prolonged life span (by 15-20%). In contrast, older MSCs failed to prolong life span at all.

Thus, it seems that stem cells, like the rest of the cells in our bodies, also suffer from the ravages of time. Stems cells (of various types) collected from younger, healthier donors are more effective for transplantation and regenerative medicine than those collected from older individuals, which makes a strong case for the preservation of stem cells at the earliest possible time, and for the consideration of donor age when transplanting stem cells.

Biography

Harris is a graduate of Wake Forest University in Winston-Salem, North Carolina where he obtained Bachelor of Science degrees (summa cum laude) in Biology, Mathematics and Psychology in 1978. He earned a Masters of Medical Sciences (summa cum laude) from Bowman Gray Medical School in 1980 and his Doctorate in Microbiology and Immunology (magna cum laude) from Bowman Gray Medical School in 1982. From 1982-1985 Dr. Harris was a Post-doctoral Fellow at the Ludwig Institute for Cancer Research in Lausanne, Switzerland. In 1985 he joined the faculty at the University of North Carolina-Chapel Hill as a Research Assistant Professor in the Department of Medicine. In 1989 Dr. Harris joined the faculty at the University of Arizona in Tucson as an Associate Professor in the Department of Microbiology & Immunology. In 1996 Dr. Harris was promoted to Professor of Immunology. Dr. Harris established the first cord blood bank in the USA in 1992. He currently serves as Director of the Cord Blood Stem Cell Bank, is a member of the Arizona Cancer Center, a member of the Children's Research Center, and a member of the Arizona Arthritis Center. Dr. Harris's research interests include stem cells and regenerative medicine, cancer research/stem cell transplantation and gene therapy. He has published more than 300 articles (papers, book chapters and abstracts), given more than 100 talks on stem cells over the past 7 years, and has served as a consultant to the governments of China, Hong Kong, Singapore and South Korea. Dr. Harris has also founded 4 companies while at the University of Arizona: Cord Blood Registry, Inc.; ImmuneRegen BioSciences, Inc.; QuteGen, Inc. and AdCyte.

davidh@email.arizona.edu
Lee Buckler
Cell Therapy Group, USA

The state of the cell therapy industry: Metrics, trends, and analysis

This presentation will review the status cell therapy industry from a number of different perspectives including the most recent data regarding the revenue being generated from commercial cell therapy products globally, the late-stage trials currently in the pipeline (by company, indication, cell-type, etc), the overall pipeline as well as some of the notable business, clinical and sector trends.

Bullet Points of Presentation Highlights – ATTENDEES WILL LEARN about:

- Commercial cell therapy products and their current revenue
- Late-stage cell therapy products in clinical development by company, indication, cell-type, etc
- Overall business, clinical and sector trends in the cell therapy industry

lbuckler@celltherapygroup.com
Gene P. Siegal
University of Alabama at Birmingham, USA

A common sense approach to the recognition and diagnosing of tumor and tumor-like conditions of bone

Even experienced pathologists are sometimes intimidated by bone biopsies. Histological similarities between reactive lesions and neoplastic processes can cause concern that a bone tumor has been overlooked or fears of under-diagnosis when tumors are present. A common sense approach to the diagnosis of bone diseases using clinical history with correlative appropriate imaging data can help minimize these concerns. In this presentation I intend on surveying interesting diagnostic problems in orthopedic pathology from patients ranging from very young to very old age. Its objectives are to enable participants to construct logical frameworks for categorizing various bone disorders and to be more comfortable in the differential diagnosis of orthopedic diseases. It is most appropriate for practicing pathologists who only see such lesions rarely and for advanced trainees. I intend to begin with a brief introduction to orient participants to the philosophy of diagnosis in orthopedic pathology and how best to put the gamut of possible diagnoses into a logical framework based upon age at presentation, clinical history, imaging parameters and histology. This will be followed by use of the case presentation format to present unknown cases by age range with the most common diagnostic categories in each range.

At the end of the session I would expect the participant to be able to:

Create a differential diagnosis of bone diseases/neoplasms based on age of patient
Create a differential diagnosis of bone diseases/neoplasms based on which bone as well as site in bone involved
Create a differential diagnosis of bone diseases/neoplasms based on imaging appearance
Recognize the most common bone lesions based on histologic criteria
Identify and differentiate the most common benign and malignant primary tumors of bone

gsiegel@uab.edu
Ukrainian experience of fetal stem cells transplantation for severe human diseases treatment: 13 years of clinical applications in legal field

In 1999 Ukrainian Parliament approved Law of Ukraine "About the Transplantation of Organs and Other Anatomical Structures to Human" that regulates the application of fetal stem cells in treatment of people in severe disease conditions. From those moment were conducted dozens of preclinical study and clinical trials on the efficacy of fetal stem cells transplantation in diseases of the heart and vascular, liver and kidney, endocrine and nervous system, blood diseases and pathology of immune system, skin, connective tissue and bones diseases, eye diseases and disturbance in hearing, pathology of stomach and intestine, pancreas and likewise treatment of reproductive system dysfunction.

This Law reviews introduction of fetal stem cells into body as transplantation, and the cells themselves as graft. Clinical trials conducted not by the schedule of implementation for pharmacological drugs, but by protocols of clinical trials of the organ transplantation i.e. first (introduction of cells to healthy people) and fourth (analysis of massive number of observation by their results of multi-center trials) phases of clinical trials are absent. As the result in short period of time developed and implemented in clinical practical the biotechnological methods of treatment in myocardial infarction (introduction of fetal stem cells in the zone of infarction and hibernating myocardium with the help of navigation system NOGA), pancreatocrosis (with the use of differentiating potential of mesenchymal stem cells from Wharton jelly to obliterate the open flow of pancreatic duct), diabetes mellitus I and II types, chronic ischemia of the lower limb, secretory and endocrine male forms of infertility, impotency, degenerative diseases of the nervous system, arterial hypertension, liver cirrhosis and many other diseases.

The indications and contra-indications (absolute and relative) developed were to application of stem cells for treatment of human diseases. Principles of deontology and medical ethics in regenerative medicine using fetal stem cells were determined. The period of treating diseases with the help of regenerative medicine, their dozes, frequencies of introduction, possible complications and side effects were established. Passports of fetal stem cells providing their biological safety were developed. Scientists of Ukraine are open for collaboration and ready to share their experiences of development in regenerative medicine using fetal stem cells.

Biography

Oleksandr L. Kukharchuk, M.D., Research Director of EmProCell Clinical Research Pvt. Ltd., visit-professor MGM University of Health Sciences, Mumbai, Professor of Medicine.

Dr. Oleksandr L. Kukharchuk was specialized as "medical practitioner" at Chernivtsi Government Medical Institute (Ukraine, Chernivtsi). GMCc. (Candidate of Medical Science) defended 1991 in the session of specialized academic council at Kaunas Medical Institute (Lithuania). D.M.Sc (Doctor of Medical Science) defended 1996 in the session of specialized academic council at Odessa Governmental Medical University (Ukraine), Associate Professor obtained on 1998; Professor obtained on 2001. 1982-1991: Assistant, Department of Pathophysiology Chernivtsi Government Medical Institute (Ukraine, Chernivtsi). 1991-1994: Senior Tutor, Normal Physiology with course of Pathophysiology at Chernivtsi Government Medical Institute (Ukraine, Chernivtsi). Head of the Central Research Laboratory and Senior Tutor of the Pathophysiology Department at Chernivtsi Government Medical Institute (Ukraine, Chernivtsi). 1994-1995: Head of Central Research Laboratory, Associate Professor of the Normal Physiology Department at Buchovian Government Medical Academy (Ukraine, Chernivtsi). 1995-1997: Director of the Centre for Scientific-Medical Investigation at Buchovian Government Medical Academy (Ukraine, Chernivtsi). 1997-2002: Head of the Normal Physiology Department at Buchovian Government Medical University (Ukraine, Chernivtsi). 2002-2009: Research Director of the Centre for Embryonic Cells 'EmCell' (Ukraine, Kiev). 2005-2006: Research Director of the Coordination Centre for Transplantation of Organs, Tissues and Cells of the Ukraine Health Ministry (Ukraine, Kiev). 2006-2010: Director of Coordination Centre for Transplantation of Organs, Tissues and Cells of the Ukraine Health Ministry; Chief Specialist of the Ukraine Health Ministry by specialization "Transplantology"; Research Director of Institute of Cell Therapy (Ukraine, Kiev), Director EmProCell Clinical Research Pvt. Ltd. (India, Mumbai).

professorgeneral@gmail.com
Hopeful dads should stop smoking at least 3 months before conception

The relevance of preconceptional and prenatal toxicant exposures for genomic stability in offspring is difficult to analyze in human populations, because gestational exposures usually cannot be separated from preconceptional exposures. To analyze the roles of exposures during gestation and conception on genomic stability in the offspring, stability was assessed via the Comet assay and highly sensitive, semiautomated confocal laser scans of γH2AX foci in cord, maternal, and paternal blood as well as spermatozoa from 39 families in Crete, Greece, and the United Kingdom. With use of multivariate linear regression analysis with backward selection, preconceptional paternal smoking (% tail DNA: $P=0.032$, γH2AX foci: $P=0.018$) and gestational maternal (% tail DNA: $P=0.033$) smoking were found to statistically significantly predict DNA damage in the cord blood of F1 offspring. Maternal passive smoke exposure was not identified as a predictor of DNA damage in cord blood, indicating that the effect of paternal smoking may be transmitted via the spermatozoal genome. Taken together, these studies reveal a role for cigarette smoke in the induction of DNA alterations in human F1 offspring via exposures of the fetus in utero or the paternal germline. Moreover, the identification of transgenerational DNA alterations in the unexposed F1 offspring of smoking-exposed fathers supports the claim that cigarette smoke is a human germ cell mutagen.

Biography

Professor Diana Anderson currently holds the Established Chair of the Division of Biomedical Sciences at the University of Bradford, UK. She obtained her first degree in the University of Wales and second degrees in the Faculty of Medicine, University of Manchester. After tutoring at the University of Sydney, Australia, she became a research worker in the Department of Cancer Studies at the University of Leeds and at the Paterson Laboratories, Christie Hospital, Manchester. In 1974, she was appointed as Head of Mutagenesis Studies at ICI’s Central Toxicology Laboratory. She joined BIBRA International in 1981 as Head of Genetic and Reproductive Toxicology and became Assistant Director and Group Forum Co-ordinator in 1987. In 1992, she became Senior Associate and Co-ordinator of External Affairs at BIBRA. She has attended various management courses. She has served on the editorial board of 8 international journals plus 2 on line journals, has over 400 publications, has edited/authored 8 books and guest-edited 9 special issues of 4 international journals. She is Series Editor of books in Current Toxicology for John Wiley and Sons and Issues in Toxicology for the Royal Society of Chemistry. She is an active Committee member and has been Vice-President of the Institute of Biology. She has successfully supervised 26 PhD students and is currently supervising other PhDs and has managed several post-doctoral positions. She has been external examiner for 29 PhDs and was External Examiner for the Dept. of Genetics, University of Wales, Swansea. She has been invited to speak at many international meetings and chair numerous symposia. She has helped establish new research laboratories in India and Korea under the auspices of the British Council and UNIDO. Funded by various international agencies, scientists from America, Australia, the Czech Republic, Italy, India, Iran, Korea, Poland, Serbia, Spain and Turkey have received training under her supervision. She has organised both national and international meetings and was a member of various national (e.g. MRC Advisory Board, Veterinary Products Committee) and was of international committees, including the European Union Scientific Committee for Animal Nutrition (SCAN). She recently won a prize as an Enterprise Fellow. She has hosted and participated in 56 meetings for WHO/JPCs. She is a consultant for many international organisations, such as the WHO, NATO, TWAS, UNIDO and the OECD.

D.Anderson1@bradford.ac.uk
2nd World Congress on
Cell Science & Stem Cell Research
November 12-14, 2012 Hilton San Antonio Airport, USA

Scientific Tracks & Abstracts
### Session Introduction

**Title:** Genetic determinants of breast cancer stem cells defined in mice  
Richard G. Pestell, Kimmel Cancer Center, USA

**Title:** Autologous cord blood infusions for the treatment of pediatric stroke and cerebral palsy  
David T. Harris, University of Arizona, USA

**Title:** Estrogen mediated epigenetic modifications: Role in breast cancer therapy  
Ratna K Vadlamudi, University of Texas Health Sciences Center at San Antonio, USA

**Title:** KDM1 is a novel therapeutic target for the treatment of gliomas  
Gangadhara Reddy Sareddy, University of Texas Health Science Center, USA

**Title:** Delivering cytokine gene therapy to prostate tumors using adipose-derived mesenchymal stem cells  
Marxa L. Figueiredo, University of Texas, USA

**Title:** Targeting neural stem cells in situ to correct the neurological disorders in Atm-null mice  
Paul K. Wong, UT MD Anderson Cancer Center, USA

**Title:** Extracellular mechanical forces ruling the stem-ness of human adult mesenchymal stem cells  
Maryam Niapour, Adisave, Canada

**Title:** Glucose metabolism and vascular progenitors: A link to stem cell kinetics  
Madhulika Dixit, Indian Institute of Technology, India

**Title:** Analysis of TLR4 signaling and PI3K/Akt pathway activation in renal cancer cell line: A clinical approach  
Jatawa S K, Rajiv Gandhi Proudyogiki Vishwavidyalaya, India

**Title:** The use of autologous mesenchymal stromal cells for treatment of neurodegenerative disorders - past achievements and future goals  
Shimon Slavin, International Center for Cell Therapy & Cancer Immunotherapy (CTCI), Israel

**Title:** Role of cardiac Sca-1+ cells in cardiac homeostasis and injury  
Morayma Reyes, University of Washington, USA

**Title:** Therapeutic potential of genetically modified stem cells: Role of arginine decarboxylase  
Jong Eun Lee, Yonsei University, South Korea

**Title:** Transplantation of human iPS cells generate dopamine neurons and reduce the behaviour impairment in rat model of Parkinson’s disease  
Sabesan, M, Annamalai University, India
The role of bone marrow transplantation on oocyte-granulosa cell interaction and follicular development of cisplatin-induced ovarian failure in rat
Hendarto H, Komarhadi MF, Darmawanti E, Widjiati R, Suhatno and Rantam FA
University of Airlangga Surabaya, Indonesia

Introduction: Infertility is one of the consequence of chemotherapy in cancer patients due to its cytotoxic effect that induces acute follicular damage, abnormal folliculogenesis leading to ovarian failure. Two crucial growth factors in abnormal folliculogenesis namely Growth Differentiation Factor-9 (GDF-9) and Stem Cell Factor (SCF), which act on the oocyte-granulosa cell interaction, will be disrupted and in turn it will affect follicular development. In this study we try to evaluate whether bone marrow transplantation (BMT) has a role on oocyte-granulosa cell interaction by analyzing GDF-9 and SCF expressions and also follicular development by analyzing primordial, primary, secondary and graafian follicles of experimental cisplatin-induced ovarian failure in rat.

Design: Animal laboratory experimental study

Materials and Methods: Forty eight rats (rattus norvegicus strain wistar) were divided into three groups : control, cisplatin and cisplatin+BMT. Ovarian failure was induced by administration of intraperitoneal cisplatin dose 5 mg/kg body weight for 1 week. BMT 2x10^7 cell was injected through rat tail vein after cisplatin administration. Bone marrow was isolated from rat femur 6-12 weeks of age and characterized by CD44(+), CD45(-), CD105(+). Immunohistochemistry examinations for ovarian GDF-9, SCF and follicle development evaluation were performed after 2 weeks of BMT injection. All three groups datas were compared using the Anova test.

Results: The expressions of GDF-9 (15.91 ± 0.69) and SCF (20.26 ± 1.14) in cisplatin+BMT group were higher than those in cisplatin group: (5.33 ± 1.76) and (12.27 ± 2.88) and control group: (14.53 ± 1.42) and (20.22 ± 2.14) (p=0.000).

In cisplatin+BMT group the number of primordial (5.31 ± 1.30), primary (4.37 ± 0.88), secondary (3.62 ± 0.71) and graafian follicles (2.75 ± 0.85) were higher than those in cisplatin group: (4.31 ± 1.19), (3.81 ± 1.22), (2.87 ± 0.95) and (0.37 ± 0.69); but were lower than those in control group (6.12 ± 1.20), (4.93 ± 1.61), (4.25 ± 0.77) and (5.81 ± 1.37) (p=0.000).

Positive PKH labeling was seen in cisplatin+BMT group, while negative result in cisplatin group.

Conclusion: On cisplatin-induced ovarian failure in rat, bone marrow transplantation may improve oocyte-granulosa cell interaction and follicular development. Further study is needed

Biography
Hendi Hendarto has completed his Ph.D in medical science (2007) from University of Airlangga Surabaya. He is supervisor of Graha Amerta IVF Clinic at Dr Soetomo Hospital and also Head of Department of Obstetric and Gynecology University of Airlangga Surabaya, Indonesia